Current status of mood stabilizers in the management of bipolar II disorder

Bipolar II Disorder: Modelling, Measuring and Managing, Second Edition

Volumn , Issue , 2012, Pages 114-125

  Hadjipavlou, George ^a   Bond, David J ^a   Yatham, Lakshmi N ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84889089047     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9781139003315.012     Document Type: Chapter

References (67)

1. Amsterdam, J. D. and Shults, J. (2010). Ei cacy and safety of long-term l uoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebosubstitution study. American Journal of Psychiatry, 167, 792–800.
2. Amsterdam J. D., Wang C. H., Shwarz M. and Shults J. (2009).Venlafaxine versus lithium monotherapy of rapid and non-rapid cycling patients with bipolar II major depressive episode: a randomized, parallel group, open-label trial. Journal of Affective Disorders, 112, 219–230.
3. Angst, J. (1998). The emerging epidemiology of hypomania and bipolar II disorder. Journal of Affective Disorders, 50, 143–151.
4. Baldessarini, R. J. and Tondo, L. (2000). Does lithium therapy still work? Evidence of stable responses over three decades. Archives of General Psychiatry, 57, 187–190.
5. Baldessarini, R. J., Tondo, L., Floris, G. and Hennen, J. (1998). Ef ects of rapid cycling on response to lithium maintenance treatment in 360 Bipolar I and II disorder patients. Journal of Af ective Disorders, 155, 1434–1436.
6. Baldessarini, R. J., Tondo, L. and Hennen, J. (2001). Treating the suicidal patient with bipolar disorder: reducing suicide risk with lithium. Annals of the New York Academy of Sciences, 932, 24–38.
7. Baldessarini, R. J., Leahy L., Arcona S. et al. (2007). Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatric Services, 58, 85–91.
8. Bauer, M. S. and Mitchner, L. (2004). What is a ‘mood stabilizer’ ? An evidence-based response. American Journal of Psychiatry, 161, 3–18.
9. Bond, D. J., Noronha, M. M., Kauer-Sant’Anna, M. et al. (2008). Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis. Journal of Clinical Psychiatry, 69, 1589–1601.
10. Bond, D. J., Lam, R. W. and Yatham, L. N. (2010). Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis. Journal of Affective Disorders, 124, 228–234.
11. Brown, E. S. (2005). Bipolar disorder and substance abuse. Psychiatric Clinics of North America, 28, 415–425.
12. Brown, E. S., Nejtek, V. A., Perantie, D. C., Orsulak, P. J. and Bobadilla, L. (2003). Lamotrigine in patients with bipolar disorder and cocaine dependence. Journal of Clinical Psychiatry, 64, 197–201.
13. Calabrese, J. R., Bowden, C. L., McElroy, S. L. et al. (1999). Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. American Journal of Psychiatry, 156, 1019–1023.
14. Calabrese, J. R., Suppes, T., Bowden, C. L. et al. (2000). A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapidcycling bipolar disorder. Lamictal 614 Study Group. Journal of Clinical Psychiatry, 61, 841–850.
15. Calabrese, J. R., Shelton, M. D., Rapport, D. J. et al. (2005). A 20-month, doubleblind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. American Journal of Psychiatry, 162, 2152–2161.
16. Carney, S. M. and Goodwin, G. M. (2005). Lithium– a continuing story in the treatment of bipolar disorder. Acta Psychiatrica Scandinavica, 111 (Suppl. 426), S7–S12.
17. Dunner, D. L., Stallone, F. and Fieve, R. R. (1982). Prophylaxis with lithium carbonate: an update. Archives of General Psychiatry, 39, 1344–1345.
18. Fieve, R. R., Kumbaraci, T. and Dunner, D. L. (1976). Lithium prophylaxis of depression in Bipolar I, Bipolar II, and unipolar patients. American Journal of Psychiatry, 133, 925–929.
19. Frankenburg, F. R. and Zanarini, M. C. (2002). Divalproex sodium treatment of women with Borderline Personality Disorder and Bipolar II: a double-blind placebocontrolled pilot study. Journal of Clinical Psychiatry, 63, 442–446.
20. Frye, M. A., Ketter, T. A., Kimbrell, T. A. et al. (2000). A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. Journal of Clinical Psychopharmacology, 20, 607–614.
21. Geddes, J. R., Calabrese, J. R. and Goodwin, G. M. (2009). Lamotrigine for treatment of bipolar depression: independent metaanalysis and meta-regression of individual patient data from i ve randomised trials. British Journal of Psychiatry, 194, 4–9.
22. Ghaemi, S. N. and G oodwin, F. K. (2001). Gabapentin treatment of the non-refractory bipolar spectrum: an open case series. Journal of Affective Disorders, 65, 167–171.
23. Ghaemi, S. N., Katzow, J. J., Desai, S. P. and Goodwin, F. K. (1998). Gabapentin treatment of mood disorders: a preliminary study. Journal of Clinical Psychiatry, 59, 426–429.
24. Ghaemi, S. N., Hsu, D. J., h ase, M. et al. (2006 a). Pharmacological treatment patterns at study entry for the i rst 500 STEP-BD participants. Psychiatric Services, 57, 660–665.
25. Ghaemi, S. N., Schrauwen, E., Klugman, J. et al. (2006b). Long-term lamotrigine plus lithium for bipolar disorder: one year outcome. Journal of Psychiatric Practice, 12, 300–305.
26. Glaxo SmithKline (2006). A multicenter, doubleblind, placebo-controlled, i xed-dose, eightweek evaluation of the ei cacy and safety of lamotrigine in the treatment of major depression in patients with Type II bipolar disorder. http://ctr.gsk.co.uk accessed 17/08/2011.
27. Goodwin, F. K., Fireman, B., Simon, G. E. et al. (2003). Suicide risk in bipolar disorder during treatment with lithium and divalproex. Journal of the American Medical Association, 290, 1467–1473.
28. Greil, W. and Kleindienst, N. (1999). Lithium versus carbamazepine in the maintenance treatment of bipolar II disorder and bipolar disorder not otherwise specii ed. International Clinical Psychopharmacology, 14, 283–285.
29. Hadjipavlou, G. H. and Yatham, L. (2004). Bipolar II Disorder: an overview of recent developments. Canadian Journal of Psychiatry, 49, 802–812.
30. Jacobsen, F. M. (1993). Low-dose valproate: a new treatment for cyclothymia, mild rapid-cycling disorders, and premenstrual syndrome. Journal of Clinical Psychiatry, 54, 229–234.
31. Judd, L. L., Akiskal, H. S., Schettler, P. J. et al. (2003). A prospective investigation of the natural history of the long-term weekly symptomatic status of Bipolar II Disorder. Archives of General Psychiatry, 60, 261–269.
32. Judd, L. L., Akiskal, H. S., Schettler, P. J. et al. (2005). Psychosocial disability in the course of Bipolar I and II Disorders. A prospective, comparative, longitudinal study. Archives of General Psychiatry, 62, 1322–1330.
33. Kane, J. M., Quitkin, F. M., Rifkin, A. et al. (1982). Lithium carbonate and imipramine in the prophylaxis of unipolar and Bipolar II illness: a prospective, placebo-controlled comparison. Archives of General Psychiatry, 39, 1065–1069.
34. Kleindienst, N. and Greil, W. (2000). Dif erential ei cacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: results of the MAP study. Neuropsychobiology, 42 (Suppl. 1), S2–S10.
35. Kupka, R. W., Altshuler, L. L., Nolen, W. A. et al. (2007). h ree times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disorders, 9, 531–535.
36. Malhi, G. S., Mitchell, P. B., Berk, M. and Goodwin, G. M. (2005). Mood stabilizers: a labile label. Acta Psychiatrica Scandinavica, 111 (Suppl. 426), S5–S6.
37. Margolese, H. C., Beauclair, L., Szkrumelak, N. and Chouinard, G. (2003). Hypomania induced by adjunctive lamotrigine. American Journal of Psychiatry, 160, 183–184.
38. McElroy, S. L., Martens, B. E., Creech, R. S. et al.(2010a). Randomized, double-blind, placebo-controlled study of divalproex extended release loading monotherapy in ambulatory bipolar spectrum disorder patients with moderate-to-severe hypomania or mild mania. Journal of Clinical Psychiatry, 71, 557–565.
39. McElroy, S. L., Martens, B. E., Winstanley, E. L. et al. (2010b). Placebo-controlled study of quetiapine monotherapy in ambulatory bipolar spectrum disorder with moderate-to-severe hypomania or mild mania. Journal of Af ective Disorders, 124, 157–163.
40. McElroy, S. L., Weisler, R. H., Chang, W. et al. (2010c). A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). Journal of Clinical Psychiatry, 71, 163–174.
41. McIntyre, R. S., Mancini, D. A., McCann, S. et al. (2002). Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disorders, 4, 207–213.
42. McIntyre, R. S., Riccardelli, R. and Binder, C. (2005). Open-label adjunctive topiramate in the treatment of unstable bipolar disorder. Canadian Journal of Psychiatry, 50, 415–422.
43. National Institute for Health and Clinical Excellence (NICE) (2006). Bipolar disorder. NICE clinical guideline 38. http://www.nice. org.uk/CG38, accessed 17/08/11.
44. Nemerof, C. B., Evans, D. L., Gyulai, L. et al. (2001). Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. American Journal of Psychiatry, 158, 906–912.
45. Nierenberg, A. A., Ostacher, M. J., Calabrese, J. R. et al. and STEP-BD Investigators (2006). Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, for risperidone. American Journal of Psychiatry, 163, 210–216.
46. Quitkin, F., Rikfin, A., Kane, J., Ramos-Lorenzi, J. R. and Klein, D. F. (1978). Prophylactic ef ect of lithium and imipramine in unipolar and Bipolar II patients: a preliminary report. American Journal of Psychiatry, 135, 570–572.
47. Rubio, G., Lopez-Munoz, F. and Alamo, C. (2006). Ef ects of lamotrigine in patients with bipolar disorder and alcohol dependence. Bipolar Disorders, 8, 289–293.
48. Schaf er, A., Zuker, P. and Levitt, A. (2006). Randomised, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. Journal of Af ective Disorders, 96, 95–99.
49. Suppes, T., Brown, E. S., McElroy, S. L. et al. (1999). Lamotrigine for the treatment of bipolar disorder: a clinical case series. Journal of Af ective Disorders, 53, 95–98.
50. Suppes, T., Hirschfeld, R. M., Vieta, E. et al. (2008a). Quetiapine for the treatment of bipolar II depression: analysis of data from two randomized, double-blind, placebo-controlled studies. World Journal of Biological Psychiatry, 9, 198–211.
51. Suppes, T., Marangell, L. B., Bernstein, I. H. et al. (2008b). A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. Journal of Affective Disorders, 111, 334–343.
52. Thase, M. (2005). Bipolar depression: issues in diagnosis and treatment. Harvard Review of Psychiatry, 13, 257–271.
53. Tondo, L., Baldessarini, R. J., Hennen, J. and Floris, G. (1998). Lithium maintenance treatment of depression and mania in Bipolar I and Bipolar II disorders. American Journal of Psychiatry, 155, 638–645.
54. Tondo, L., Baldessarini, R. J. and Floris, G. (2001). Long-term clinical ef ectiveness of lithium maintenance treatment in Types I and II bipolar disorders. British Journal of Psychiatry, 41 (Suppl. 178), S184–S190.
55. van der Loos, M., Nolen, W. A. and Vieta, E. (2006). Lamotrigine as add-on to lithium Chapter 11: Mood stabilisers in Bipolar II disorder 125 in bipolar depression. Paper presented at the fifth European Stanley Conference on Bipolar Disorder, Barcelona, 5–7 October.
56. van der Loos, M. L., Mulder, P., Hartong, E. G. et al. (2010). Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine. Acta Psychiatrica Scandinavica, 122, 246–254.
57. van der Loos, M. L., Mulder, P., Hartong, E. G. et al. (2011). Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design. Bipolar Disorders, 13, 111–117.
58. Vieta, E., Gast ó, C., Colom, F. et al. (2001). Role of risperidone in bipolar II: an open 6-month study. Journal of Af ective Disorders, 67, 213–219.
59. Vieta, E., Sanchez-Moreno, J., Goikolea, J. M. et al. (2003). Adjunctive topiramate in Bipolar II Disorder. World Journal of Biological Psychiatry, 4, 172–176.
60. Vieta, E., Goikolea, J. M., Martinez-Aran, A. et al. (2006). A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. Journal of Clinical Psychiatry, 67, 473–477.
61. Winsberg, M. E., DeGolia, S. G., Strong, C. M. and Ketter, T. A. (2001). Divalproex therapy in medication-naïve and mood-stabilizernaïve Bipolar II depression. Journal of Af ective Disorders, 67, 207–212.
62. Yatham, L. (2005). Diagnosis and management of patients with Bipolar II Disorder. Journal of Clinical Psychiatry, 66 (Suppl. 1), S13–S17.
63. Yatham, L. N., Kennedy, S. H., O’Donovan, C. et al. (2005). Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: Consensus and controversies. Bipolar Disorders, 7 (Suppl. 3), S5–S69.
64. Yatham, L. N., Kennedy, S. H., Schaf er, A. et al. (2009). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disorders, 11, 225–255.
65. Young, A. H., McElroy, S. L., Bauer, M. et al. (2010). A double-blind, placebo controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). Journal of Clinical Psychiatry, 71, 150–162.
66. Young, L. T., Robb, J. C., Hasey, G. M. et al. (1999). Gabapentin as an adjunctive treatment in bipolar disorder. Journal of Af ective Disorders, 55, 73–77.
67. Young, L. T., Jof e, R. T. and Robb, J. C. (2000). Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. American Journal of Psychiatry, 157, 124–126.